# AI Patent Inventorship Strategy: How Do You Protect AI-Assisted Drug Discovery?

patentreviewpro.com · October 15, 2026

> USPTO Guidance Reshapes Inventorship The USPTO's February 2024 inventorship guidance, and the updates that followed, have forced drug discovery teams...

## USPTO Guidance Reshapes Inventorship

The USPTO's February 2024 inventorship guidance, and the updates that followed, have forced drug discovery teams to rethink how they document and protect AI-assisted inventions. The core principle is unchanged: only natural persons can be named inventors, and patent applications must identify significant human contribution. But in practice, the guidance raises hard questions for computational pipelines where an AI model proposes candidate molecules and a human selects, synthesizes, and validates them. Attorneys at Crowell & Moring and Holland & Knight have both emphasized that companies should be recording who prompted the model, how prompts were refined, and what human judgment shaped the final compound selection, because that record is what establishes inventorship if the patent is ever challenged.

**Also worth reading:** [How Does Revised USPTO Guidance Define Inventorship in AI-Assisted Inventions?](https://patentreviewpro.com/knowledge/how_does_revised_uspto_guidance_define_inventorship_in_ai-assisted_inventions.php) · [How Are AI Inventorship Legal Standards Reshaping Patent Review and Prosecution?](https://patentreviewpro.com/knowledge/how_are_ai_inventorship_legal_standards_reshaping_patent_review_and_prosecution.php) · [Is AI Inventorship Patent Eligibility the Next Big Hurdle for AI Patent Applications?](https://patentreviewpro.com/knowledge/is_ai_inventorship_patent_eligibility_the_next_big_hurdle_for_ai_patent_applications.php)

For pharmaceutical companies, the strategic response is twofold. First, draft claims that center on the human contributions—the synthesis route, the therapeutic use, the experimental validation—rather than the AI's output alone, a drafting approach IPWatchdog recommends for surviving future guidance cycles. Second, consider whether trade secret protection better fits the AI models and training data themselves, which may never qualify for patent protection. Reuters commentary has noted that discovery-stage AI outputs sit in a gray zone, making layered protection—patents on human-driven innovations, trade secrets on the models—increasingly the default playbook.

## Human Contribution Remains Patent Bedrock

The USPTO’s recent clarifications confirm that AI-assisted drug discovery does not lower the bar for inventorship. Under current guidance, a human must have contributed significantly to each claim, meaning AI cannot be named as an inventor and purely machine-generated output remains unpatentable. For drug developers, this demands meticulous documentation of human reasoning behind candidate selection, assay design, and structural optimization. Strategies should focus on framing claims around the human’s inventive contribution—such as problem framing, training data curation, or interpreting AI outputs—rather than the AI’s computational speed.

Trade secret protection offers a complementary path when patentable human contribution is thin. However, disclosure obligations and reverse-engineering risks complicate that choice. As Crowell & Moring and Holland & Knight note, the safest approach is drafting claims that survive multiple guidance cycles by anchoring them in tangible human decisions. Solo practitioners and independent inventors, now served by platforms like Esgenix, must treat inventorship logs as core IP assets. Ultimately, AI is a tool; the patent monopoly still rewards the human mind that directs it.

## AI Drug Discovery Trade Secret Choices

Companies deploying AI in drug discovery face a fundamental strategic fork: patent the invention or hold it as a trade secret. Recent USPTO guidance confirms that AI-assisted inventions remain patentable so long as a natural person made a significant contribution, which pushes discovery teams to document human involvement in prompt design, model selection, and candidate validation. Patents offer exclusivity but require disclosure of training data strategies and model architectures that competitors could study, a serious concern when the underlying algorithm may be more valuable than any single compound it identifies.

Trade secret protection, by contrast, preserves proprietary datasets, fine-tuned models, and screening pipelines indefinitely, but only with rigorous confidentiality controls, employee agreements, and vendor management. Many drug discovery firms adopt a hybrid approach, patenting validated compounds and therapeutic uses while shielding the AI methodology itself. As USPTO inventorship scrutiny intensifies and courts refine the human contribution standard, counsel should audit which discoveries merit disclosure and which belong behind locked doors before filing decisions lock in the choice.

## Drafting Claims Beyond Guidance Cycles

For AI-assisted drug discovery, inventorship turns on human contribution, not whether AI was used. Under recent USPTO clarifications, inventors must be natural persons who conceived the claimed invention; AI remains a tool. Protect inventions by documenting target selection, hypothesis design, experimental validation, and lead optimization. AI Patent Review at patentreviewpro.com emphasizes drafting claims around human-designed inputs and outputs, not pure AI-generated correlations. This creates a prosecution record showing meaningful human conception even as guidance shifts.

Pair patents with trade secrets for models, weights, training data, and negative results. File claims covering compounds, methods, biomarkers, and workflows while keeping logs of human oversight and reduction to practice. If AI merely suggests a candidate, inventors still need specific human contributions. Because each guidance cycle may alter disclosure and inventorship standards, build a portfolio flexible enough to survive the next cycle and the one after that. That is how AI-assisted drug discovery stays protected.

## Solo Inventor AI Patent Workflows

AI Patent Inventorship Strategy: How Do You Protect AI-Assisted Drug Discovery? The USPTO's recent guidance confirms that AI systems cannot be named as inventors, yet human contribution must be more than merely owning the AI or posing a problem. For solo inventors and independent practitioners, this creates a documentation burden: you must show conception occurred in your mind, with AI as a tool akin to a calculator or lab instrument. Crowell & Moring and Holland & Knight both stress that inventorship turns on human intellectual contribution, not algorithmic output.

Protection strategy therefore splits between patents and trade secrets. Patent claims should focus on the human-designed experimental framework, target selection rationale, and validation steps, not on raw model outputs that may be obvious or non-enabled. Where disclosure risks exposing a proprietary training pipeline, trade secret protection may be stronger. Esgenix's decision to open AI patent workflows to solo practitioners signals growing demand for tools that timestamp human decisions. Drafting must anticipate future guidance cycles, building a record of conception that survives scrutiny.

## AI Inventorship Strategy Comparison

| Strategy | Key Approach | Trade-offs |
| --- | --- | --- |
| Human-Driven Inventorship Framing | Document substantial human contribution in prompt design, target selection, and validation to satisfy USPTO guidance | Strong patent eligibility, but requires meticulous inventorship records and may undervalue the AI's role |
| Trade Secret Protection | Keep AI models, training data, and discovery workflows confidential rather than filing patents | No disclosure or expiration, but weak against reverse engineering and independent discovery |
| Hybrid Portfolio Strategy | Patent human-validated compounds and methods while shielding AI pipelines as trade secrets | Balances exclusivity and secrecy, but demands careful internal governance and clean IP separation |
| Joint Ownership / Licensing | Clarify rights among AI developers, pharma partners, and research institutions via agreements | Enables collaboration and monetization, but risks disputes over inventorship and data rights |

For AI-assisted drug discovery, the USPTO's recent guidance makes clear that patents hinge on demonstrating significant human contribution, so companies should meticulously document researcher involvement in target selection, model tuning, and compound validation. A hybrid strategy—patenting human-validated inventions while protecting AI workflows as trade secrets—offers the most durable protection, provided organizations maintain rigorous inventorship records and clear contractual allocation of rights among collaborators.

## Quick answers

### Can AI be named as an inventor under USPTO guidance?

No, USPTO guidance requires at least one natural person to make a significant contribution to each claimed invention.

### What evidence proves human inventorship in AI-assisted inventions?

Document prompts, selections, modifications, and experimental validation showing the human’s significant contribution.

### When should AI drug discovery inventions be kept as trade secrets?

Trade secrets may fit when the AI model or data is hard to reverse engineer and public disclosure would forfeit value.

### How can AI patent claims survive evolving USPTO guidance?

Draft claims around concrete human-designed improvements, technical effects, and detailed enablement rather than abstract AI outputs.

Canonical: https://patentreviewpro.com/knowledge/ai_patent_inventorship_strategy_how_do_you_protect_ai-assisted_drug_discovery.php
Markdown: https://patentreviewpro.com/knowledge/ai_patent_inventorship_strategy_how_do_you_protect_ai-assisted_drug_discovery.php/index.md